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ABSTRACT: Prion diseases such as bovine spongi-
form encephalopathy, chronic wasting disease, and 
scrapie pose serious risks to human and animal health 
due to a host of disease-specific factors, including the 
resistance of infectious prions (PrPSc) to natural degra-
dation and to most commercial inactivation procedures. 
In an attempt to address this concern, a mouse model 
was used to compare the efficacy of an alkaline hydro-
lysis process with a simulated continuous-flow render-
ing treatment for disposal of PrPSc-infected biological 
material. Female C57/BL6 mice (N = 120) were ran-
domly divided into 4 treatment groups (n = 30), and 
each mouse was injected intraperitoneally with their 
designated treatment inoculum. Treatment groups 
1 and 2 served as the positive and negative controls, 
respectively. Group 3 was inoculated with rendered 
scrapie-positive mouse brain material to investigate 
the effectiveness of simulated continuous-flow render-
ing practices to reduce or eliminate PrPSc. Group 4 
was inoculated with hydrolyzed scrapie-positive mouse 
brain material to determine the sterilizing effect of al-
kaline hydrolysis on PrPSc. Mice were monitored for 
overt signs of disease, and those showing clinical signs 
were killed to prevent undue suffering. Brains were ob-
tained from all mice that died (or were killed) and ana-
lyzed with an ELISA for the presence of PrPSc. Results 
indicated that the simulated continuous-flow rendering 
treatment used for preparing the rendering treatment 
group inoculum failed to completely eliminate PrPSc. 
Rendering delayed, but did not stop, clinical mouse-
adapted scrapie transmission. Compared with positive 
controls, the rendering treatment group experienced an 
approximate 45-d average delay in days to death (250 
vs. 205 d for positive controls; P < 0.0001) and a death 
loss of 73.9% (P = 0.0094). Positive controls suffered 
100% death loss. The results validated the efficacy of 
the alkaline hydrolysis treatment to inactivate all PrPSc 
because no alkaline hydrolysis treatment group mice 
succumbed to the disease (P < 0.0001). Based on our 
results, alkaline hydrolysis should be considered by the 
animal rendering and beef packing industries as an al-
ternative to incineration, landfill burial, and rendering 
for disposing of biological material potentially infected 
or contaminated with prion disease.
Key words:  alkaline hydrolysis, commercial rendering, mouse model, prion inactivation
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INTRODUCTION
After the discovery of bovine spongiform encephal-
opathy (BSE) in the United States, the Food and Drug 
Administration (FDA) published a proposed rule in 
the Federal Register in October 2005 that would pro-
hibit certain cattle-derived materials from being in-
cluded in the food and feed of all animals. The Final 
Rule of the FDA was published on April 25, 2008 and 
will take effect on April 27, 2009 (DHHS-FDA, 2008). 
Under the enhanced feed regulations, the list of pro-
hibited materials includes the entire carcass of BSE-
positive cattle, the brains and spinal cords from cattle 
30 mo of age and older, and “the entire carcass of cat-
tle not inspected and passed for human consumption 
that are 30 mo of age or older from which brains and 
spinal cords were not removed” (among other identi-
fied materials; DHHS-FDA, 2008). Using USDA-NASS 
(2008a,b) production and population statistics as well 
as the estimate reported by Roeber et al. (2001) for the 
percentage of nonambulatory disabled cattle offered for 
slaughter, the proposed rule of the FDA would pro-
hibit the heads (including the brain) and spinal cords 
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from the 6.23 million cows and bulls slaughtered; the 
entire carcass of approximately 1.86 million on-farm 
cattle mortalities; the entire carcass of approximately 
49,800 nonambulatory cows and bulls condemned at 
antemortem inspection; all inedible offal products from 
noninspected slaughter facilities (150,000 cattle); and 
the heads (including the brain) and spinal cords from 
the small proportion of fed steers and heifers that are 
identified as being 30 mo of age and older from entering 
the animal feed system.
As a consequence of the new feed regulations, those 
cattle-derived materials prohibited from use in animal 
feeds will need to be disposed of by means other than 
rendering. Alkaline hydrolysis may have potential as an 
alternative to rendering for disposing of these poten-
tially infectious tissues and animal carcasses. There-
fore, the objective was to use a murine-based model to 
compare the efficacy of an alkaline hydrolysis process 
to a simulated continuous-flow rendering treatment for 
disposal of biological material infected with mouse-
adapted scrapie.
MATERIALS AND METHODS
Animal procedures were approved by the Colorado 
State University Animal Care and Use Committee and 
the USDA-APHIS-Wildlife Services-National Wildlife 
Research Center (NWRC) Institutional Animal Care 
and Use Committee.
Treatment Group Inocula
A known mouse-adapted scrapie-positive (C57/BL6) 
mouse brain (once passed from original mice obtained 
from Rocky Mountain Laboratories, Hamilton, MT) 
was removed from −70°C storage (Revco, Thermo 
Electron Corporation, Asheville, NC) and homogenized 
into a slurry with a sterilized scalpel blade. The mouse 
brain homogenate was divided into 3 portions using 
a scientific balance (Sartorius Microbalance, Sarto-
rius Ltd., Epsom, United Kingdom) and each portion 
(~0.110 g) was randomly assigned to the positive con-
trol, rendering, or alkaline hydrolysis treatment groups. 
Homogenized treatment samples were placed in 200-µL 
PCR tubes (Eppendorf North America, Westbury, NY) 
and refrozen at −70°C until the next stage of the ex-
periment. All treatment group inocula (including the 
inoculum for the negative control treatment group) 
were diluted after their respective treatments with 10% 
(wt/vol) PBS (Difco, Becton, Dickinson and Company, 
Franklin Lakes, NJ) to a final volume of 16 mL. The 
final concentration of brain matter in the treatment 
group inocula was 6.25 µg of brain matter per micro-
liter.
Positive and Negative Control Treatment 
Groups. One-third of the scrapie-positive mouse 
brain homogenate was left untreated, transferred to a 
Dounce tissue grinder (Kimble/Kontes, Vineland, NJ), 
and ground further with a small volume of PBS. Af-
ter homogenization, the brain homogenate solution was 
transferred to a sterile 50-mL centrifuge tube (Thermo 
Fisher Scientific Inc., Waltham, MA), and additional 
PBS was added to achieve a final volume of 16 mL. 
This sample served as the inoculum for the positive 
control treatment group.
The negative control treatment group mouse brain 
(~0.100 g) originated from a known scrapie-negative 
mouse that was used in a previous study and known to 
never have been exposed to infectious prions (PrPSc). 
The mouse brain homogenate was diluted with PBS to 
achieve a final inoculum volume of 16 mL.
Rendering Treatment Group. The purpose of 
the rendering treatment was to evaluate the efficacy 
of simulated continuous-flow rendering to inactivate 
PrPSc. The continuous cooker is an agitated vessel that 
raises the temperature of raw material to 115 to 145°C 
over a 45- to 90-min period, evaporating moisture, as 
well as releasing fat from protein and bone for separa-
tion and recycling (Anderson, 2006). The continuous 
cooker was modeled in our laboratory after consulta-
tion with D. Kirstein (director of technical services, 
Darling International Inc., Des Moines, IA, personal 
communication) and K. Kage (plant manager, Darling 
International Inc., Denver, CO, personal communica-
tion). It was decided that a test tube apparatus, which 
cooked the scrapie-positive mouse brain homogenate 
in vegetable/animal shortening at a 2:1 shortening to 
brain ratio, was acceptable for representing the physi-
cal conditions of continuous-flow rendering.
A 500-mL beaker containing 350 mL of shortening 
(Great Value, Wal-Mart Stores Inc., Bentonville, AR) 
was heated to 138°C and maintained between 120 and 
138°C for the entire length of the rendering procedure. 
The temperature of the shortening was monitored by 
a suspended type-K thermocouple thermometer probe 
(Temptec Accutuff 340, Atkins Technical Inc., Gaines-
ville, FL) placed in the beaker. A test tube containing 
shortening plus scrapie-positive mouse brain homo-
genate was suspended in the beaker of heated short-
ening and agitated periodically with a piece of steel 
wire. The temperature of the contents in the test tube 
was monitored by a suspended type-K thermocouple 
(Omega Engineering Inc., Stamford, CT) attached to 
a microprocessor thermometer (model HH21, Omega 
Engineering Inc.). The temperature of the test tube 
was monitored to ensure it did not exceed 135°C, and 
the brain homogenate was cooked at this temperature 
for 45 min.
After the test tube was removed from the apparatus 
and allowed to cool, the rendered brain homogenate was 
transferred to a freezer vial, mixed with 500 µL of PBS, 
and frozen (−70°C). On the day of inoculation, the ren-
dered mouse brain homogenate was removed from fro-
zen storage, ground with a Dounce tissue grinder, and 
diluted with 15.5 mL of PBS to create the rendering 
treatment group inoculum.
Alkaline Hydrolysis Treatment Group. The 
scrapie-positive mouse brain homogenate was removed 
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from −70°C storage, thawed to ambient temperature, 
and transferred to a 200-µL PCR tube. Potassium hy-
droxide and distilled water were added to the brain ho-
mogenate in accordance with the operating instructions 
provided by the manufacturer of the alkaline hydrolysis 
unit (K. Morris, owner and chief operating officer, Hy-
drol-Pro Technologies Inc., Zephyr Hills, FL, personal 
communication). Technical grade KOH (50% wt/wt; 
Univar USA Inc., Seattle, WA) was added to the PCR 
tube until it reached 8% of the weight of the mouse 
brain homogenate; distilled water was then added until 
it reached 12% of the combined sample weight (KOH 
plus brain homogenate). The PCR tube was placed in-
side a small stainless steel module, and the module was 
sealed to prevent the possibility that brain material 
could be expelled from it during the alkaline hydrolysis 
process. The module was transported to the alkaline 
hydrolysis unit (BioMEER, Hydrol-Pro Technologies 
Inc., Zephyrhills, FL) located at the Colorado State 
University James L. Voss Teaching Hospital Veterinary 
Diagnostics Laboratory in Fort Collins. The stainless 
steel module was fastened to the wastewater collection 
rim just beneath the lid, the vessel was sealed, and the 
alkaline hydrolysis process was initiated. The alkaline 
hydrolysis vessel is designed to operate at a peak tem-
perature of 150°C and at a pressure of approximately 
4.14 bars (60 PSI). The unit used in this study is de-
signed to hydrolyze 1,818 kg (4,000 lb) of biological 
raw material (e.g., carcasses, necropsy samples, etc.) 
per cycle, in addition to the volume of KOH and wa-
ter required in the hydrolysis process. In addition to 
the 9 to 12 h that is required to bring the vessel to 
the desired temperature, the efficiency of the wastewa-
ter removal step is highly variable, which can extend 
the hydrolysis procedure to 4 or 5 d. Once the vessel 
reached its peak operating temperature (150°C), it was 
maintained at this temperature until the wastewater 
removal step was completed (weight of hydrolyzed ma-
terial is reduced to approximately 50% of the starting 
weight), at which time the effluent was discharged for 
disposal. The vessel was cooled until the module could 
be safely retrieved for transport back to the NWRC. 
The hydrolyzed material was transferred to a 50-mL 
centrifuge tube and neutralized with PBS (pH 3). Once 
the hydrolyzed sample reached a neutral pH (~8), neu-
tral PBS was added to achieve a final inoculum volume 
of 16 mL.
Mouse Model
Mice were maintained at the NWRC in cages un-
der standard rodent housing conditions (19 to 23°C, 
ambient humidity, 12:12 light:dark cycle). Mice were 
monitored twice daily according to the guidelines es-
tablished by the Animal Care and Use Committees at 
Colorado State University and the NWRC.
One hundred twenty female C57/BL6 mice (Hilltop 
Laboratory Animals, Hilltop, PA) were randomly divid-
ed into 4 groups of 30 mice each and housed in cages of 
5 mice per cage. Cages of mice were randomly assigned 
to a treatment group using a random number genera-
tor. Cage numbers, except for those cages belonging 
to the negative control treatment group, were blinded 
to prevent prejudicial judgment of disease onset. Each 
mouse was inoculated by intraperitoneal injection with 
500 µL of their designated treatment material (500 µL 
× 30 mice = 15 mL). One milliliter from each treat-
ment group inoculum was retained for Western blot 
analysis to identify the presence of PrPSc. Intraperi-
toneal inoculation was utilized for this study because 
it is a less invasive surgical procedure and has fewer 
complications associated with it than intracerebral in-
oculation. Hamir et al. (2008) explained that, whereas 
the intracerebral inoculation route gives the shortest 
incubation time, there are potential anesthesia-related 
complications and postprocedure complications such 
as intracranial hematomas and encephalitis that dis-
courage its widespread acceptance. Three mice from 
each treatment group were killed at 2 and 4 mo after 
inoculation and their brain material collected for ex-
amination of PrPSc using an ELISA and Western blot 
diagnostic assay. The remaining mice were monitored 
for overt signs of disease. Mice still living 18 mo posti-
noculation, which was the set study-termination date, 
were killed and analyzed for PrPSc.
To determine when mice were to be killed, several 
signs of clinical disease were monitored including rough 
coat, ataxia, kyphosis (hunched back), extreme lethar-
gy, stiff tail, and collapsed abdomen. Suspect signs were 
awarded 1 point and distinct signs awarded 2 points. 
When a mouse attained a score of at least 6 for a period 
of 3 consecutive days, or was assigned a single 1-d score 
of 8 or more, the mouse was killed to prevent undue 
suffering. The brain was collected from mice that died 
(from any cause) or were killed and stored at −70°C 
until assayed with an ELISA for the presence of PrPSc.
Diagnostic Assays
ELISA. The Bio-Rad CWD antigen test kit, ELI-
SA (Bio-Rad Laboratories, Hercules, CA), was used to 
confirm scrapie diagnosis in end-stage clinical mice. All 
reagents, as well as the detailed assay procedure, are in-
cluded with the purification and detection kits. Hibler 
et al. (2003) provides a very thorough explanation of 
the ELISA procedure that was helpful to this study.
Mouse brain tissue samples (350 mg ± 10 mg) were 
deposited into grinding tubes supplied by the manufac-
ture and homogenized (TeSeE Precess 48 Homogenizer, 
Bio-Rad Laboratories) for 45 s at a speed setting of 
6.5 units. Sample aliquots (250 µL) were transferred 
to 2-mL polypropylene micro test tubes, 250 µL of re-
constituted proteinase K solution was added to each 
tube, mixed by inversion, and incubated at 37°C in a 
microplate heating block for 10 min. Clarifying solution 
(250 µL) was added to each tube, again mixed by inver-
sion, and centrifuged for 7 min at 15,000 × g (20°C). 
After centrifugation, the supernatant was discarded 
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and the micro test tubes were dried by inversion onto 
absorbent paper. Resolving buffer (25 µL) was added 
to each sample and immediately incubated at 100°C for 
5 min. After incubation, micro test tubes were mixed 
with a vortex agitator for 5 s.
Sample diluent (125 µL) was added to each micro test 
tube and mixed by pipetting the sample and diluent up 
and down in the tube. A 100 µL aliquot of each diluted 
sample was added to a well in a microplate (individual 
wells coated with an anti-PrP monoclonal antibody), 
covered with adhesive film, and incubated (37°C) for 75 
min. After incubation, the adhesive film was removed, 
each well washed 3 times with 800 µL of diluted wash 
solution using an automatic washer (model 1575 Im-
munowash Microplate Washer, Bio-Rad Laboratories) 
and dried by inversion onto absorbent paper. Conju-
gate solution (100 µL) was added to each well, then 
covered with adhesive film, and incubated for 60 min 
at 4°C. At the conclusion of the incubation period, the 
adhesive film was removed, wells were washed 5 times 
with diluted wash solution (800 µL), dried by inversion 
onto absorbent paper, and 100 µL of substrate solution 
was added to each well. The microplate was then incu-
bated in the dark at ambient temperature (20°C) for 30 
min. Next, 100 µL of stop solution was added to each 
well, and the optical density was determined (model 
550 Microplate Reader, Bio-Rad Laboratories) at 450 
nm (test filter) and 620 nm (reference filter to reduce 
background absorbance).
Computer software (Microplate Manager Software v. 
5.2.1, Bio-Rad Laboratories) was used to analyze the 
results, which included calculating the mean optical 
density (OD) of the negative control and the cut-off 
value for a positive sample (mean negative control OD 
+ 0.210). However, K. Wilson (microbiologist/TSE test-
ing, Veterinary Diagnostics Laboratory, Colorado State 
University, Fort Collins, CO, personal communication) 
explained that their laboratory has reduced error asso-
ciated with performing the assay that permits using an 
OD cut-off value of 0.100. As a result, the OD value of 
0.100 was used as the cut-off value for this study.
Western Blot Assay. The Western blot diagnostic 
assay was used to identify the presence of PrPSc in the 
inocula of the different treatment groups. In addition, 
it was used to confirm the ELISA results of the 2- and 
4-mo killed mice (n = 24) and a sample of end-stage 
clinical mice (n = 13).
Samples were thawed at ambient temperature and so-
dium N-lauroyl sarkosinate was added to a final concen-
tration of 0.1% (wt/vol). Thirty-microliter aliquots were 
removed and digested with 2 units Benzonase (EMD 
Chemicals Inc., San Diego, CA) as per manufacturer’s 
instructions. Proteinase K (PK; New England Biolabs, 
Ipswich, MA) was added to a final concentration of 50 
µg/mL and digested at 37°C for 60 min. The PK reac-
tions were terminated by addition of Pefabloc [Pefabloc 
SC (AEBSF), Roche Applied Science, Indianapolis, 
IN] to 1 mM. Samples were prepared for electrophore-
sis by addition of Laemmli buffer to 1× concentration 
and incubated (90°C) for 5 min. Samples were resolved 
via SDS-PAGE gel (4–15% Tris HCl Ready Gel, Bio-
Rad Laboratories Inc., Hercules, CA) and transferred 
to polyvinylidene fluoride membranes (Immobilon-PSQ 
Transfer Membranes, Millipore Corp., Bedford, MA). 
Membranes were blocked in TBS-T (25 mM Tris, 140 
mM NaCl, 3 mM KCl, 0.05% Tween-20, pH 8.0) plus 
5% (wt/vol) nonfat milk-powder for 40 min at ambi-
ent temperature (20°C) and exposed overnight (8 h; 
4°C) to 7D9 monoclonal prion protein PrP antibody 
(Abcam Inc., Cambridge, MA) in a 1:1,000-dilution of 
prion protein antibody to TBS-T plus 1% milk-powder 
solution. Membranes were washed 3 times (5 min each) 
with TBS-T and exposed to a 1:6,666 secondary HRP-
antibody dilution (Calbiochem Goat Anti-Mouse H&L 
Chain Specific Peroxidase Conjugate, EMD Chemicals 
Inc., San Diego, CA) for 2 h at ambient temperature. 
Membranes were washed as above 3 more times and 
exposed to 1.2 mL of sensitivity substrate (SuperSignal 
West Femto Maximum Sensitivity Substrate, Thermo 
Fisher Scientific Inc., Waltham, MA) for 5 min. Mem-
branes were photographed in a dark room (EpiChem 
Darkroon, UVP BioImaging Systems, UVP Inc., Up-
land, CA) and processed (Labworks45, UVP Inc.). The 
PVDF membranes were then stained with GelCode 
Blue Stain Reagent (Thermo Fisher Scientific Inc., 
Rockford, IL) for 20 min, rinsed 10 s with 70% (vol/
vol) methanol, and dried at room temperature. This 
additional step was performed to ascertain whether any 
protein fragments and peptides remained after the ren-
dering and alkaline hydrolysis treatments.
Statistical Analysis
The PROC LIFETEST procedure (SAS Inst. Inc., 
Cary, NC) was used for the survival analysis. The 
Log-Rank test explored the homogeneity of the sur-
vival curves (i.e., days to death) across the 4 treatment 
groups (P < 0.05). Fisher’s exact test in the PROC 
FREQ procedure of SAS compared survival (i.e., delay 
in days to death) across the 4 treatment groups (P < 
0.05).
RESULTS AND DISCUSSION
The mouse model was initiated in December 2006. 
One mouse from the rendering treatment group died 
shortly after inoculation. Another mouse, this one from 
the alkaline hydrolysis treatment group, died unex-
pectedly at 150 d and was cannibalized before it could 
be removed from the cage; thus, its brain could not 
be collected for analysis. However, in the days before 
its death, the mouse did not display clinical signs of 
scrapie.
It was hypothesized that PrPSc could be detected at 
2 and or 4 mo postinoculation, which could have been 
used to establish a period of time from PrPSc infection 
to manifestation of disease. Initially, a 6-mo euthanasia 
was scheduled also, but based on the disease-negative 
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ELISA and Western blot diagnostic results from the 2- 
and 4-mo mice (data not shown), it was decided that it 
would be more valuable to leave the 6-mo mice in the 
study. Studies by White et al. (2003) and Pilon et al. 
(2007) identified the survival period for mice challenged 
by intraperitoneal injection with mouse-adapted scrapie 
that had originated from Rocky Mountain Laboratories 
to be approximately 190 to 220 d.
The ELISA-based Bio-Rad CWD antigen test kit 
confirmed the presence of PrPSc in mice that died of 
scrapie or were killed for displaying clinical signs of 
scrapie. Likewise, the ELISA confirmed that the nega-
tive control treatment group mice and alkaline hydro-
lysis treatment group mice, as well as the 6 rendering 
treatment group mice that lived to the end of the study, 
were negative for PrPSc (data not shown). The CWD 
antigen test kit is not approved for detecting scrapie 
prions nor is it approved for confirming prion disease 
in laboratory rodents, but as discovered in this study, 
the CWD antigen test kit seems capable for detecting 
mouse-adapted scrapie prions.
The primary goal of preparing the rendering treat-
ment group inoculum was to reproduce the physical 
conditions of continuous-flow rendering as closely as 
possible given the limitations of the laboratory set-
ting and the small quantity of starting material. Pre-
cautions were taken to ensure that during the 45-min 
cooking treatment the peak temperature of the mouse 
brain homogenate did not exceed 135°C. However, con-
sidering the aforementioned limitations, it is likely that 
the rendering process may have surpassed normal re-
quirements because of the time-temperature relation-
ship used in the rendering industry to guide commercial 
rendering processes. D. Kirstein (director of technical 
services, Darling International Inc., Des Moines, IA, 
personal communication) explained that the tempera-
ture of the raw material does not rise significantly until 
the water content is evaporated below 5%, at which 
point the temperature increases expeditiously to 115 
to 145°C. Rendered material exiting the cooker must 
be, at a minimum, 115°C; if this temperature is not 
achieved, the material is diverted from further process-
ing and sent through the cooker again (D. Kirstein, di-
rector of technical services, Darling International Inc., 
Des Moines, IA, personal communication). Depending 
on the rendering system and the raw material under-
going treatment, this process generally requires 45 to 
90 min of cooking (Anderson, 2006; D. Kirstein, di-
rector of technical services, Darling International Inc., 
Des Moines, IA, personal communication). Therefore, 
considering the small volume of starting material (i.e., 
one-third or ~0.110 g of the scrapie-positive mouse 
brain homogenate) used for this treatment, it is likely 
that the temperature of the mouse brain homogenate 
reached 135°C well before the end of the cooking pe-
riod. In fact, the temperature of the contents in the test 
tube reached 127°C within 5 min of being suspended in 
the beaker of heated shortening and was maintained at 
this approximate temperature until the final minutes of 
cooking when it was heated to its peak end-temperature 
of 135°C (data not shown). Under ideal circumstances, 
the excessive exposure of the mouse brain homogenate 
to the simulated rendering treatment would have been 
avoided by identifying an appropriate time-temperature 
relationship; however, given the outcome of the mouse 
model, the rendering treatment appears to have satis-
fied the needs of the study.
In Figure 1, the inoculum sample from the rendering 
treatment group that was not exposed to PK digestion 
maintained an unspecified quantity of normal prions, 
PrPSc, or both after treatment, which indicated that 
the rendering treatment did not cause excessive pro-
tein degradation. However, in the rendering treatment 
group inoculum sample that was exposed to PK diges-
tion, there appeared to be a low level of PrPSc that sur-
vived treatment (Figure 1). Results confirmed the sus-
picion that the rendering treatment was ineffective at 
eliminating all PrPSc infectivity because the rendering 
treatment group mice experienced a 45-d average delay 
in days to death (250 vs. 205 d for the positive control 
treatment group; P < 0.0001) and a 73.9% death loss 
(P = 0.0094; Figure 2). Specifically, rendering delayed, 
but did not stop, clinical mouse-adapted scrapie trans-
mission.
Previous rendering studies by Taylor et al. (1995, 
1997) achieved similar conclusions, in which they iden-
tified detectable infectivity in all scrapie-infected meat 
and bone meal samples and in 4 of 15 BSE-infected meat 
and bone meal samples after their respective render-
ing treatments. Infectivity was recovered in all samples 
subjected to the continuous-flow rendering treatments. 
Appel et al. (2001) reported that lipids protected prion 
rods against peptide-bond cleavage during autoclaving, 
which required increasing the autoclave temperature 
for prion rod samples that contained tallow to 170°C 
for 20 min to surpass the PrPSc inactivation thresh-
old. The peak temperature of the simulated continu-
ous cooker never exceeded 138°C. Although the mouse 
brain homogenate was cooked close to this temperature 
for 45 min—exceeding the necessary 20-min period; it 
is plausible that the temperature inactivation thresh-
old of PrPSc was not close enough to being breeched 
Figure 1. Western blot of the 4 treatment group inoculums ana-
lyzed with (+) and without (–) proteinase K (PK) digestion. Note: 
The circle is intended to identify the small amount of infectious prions 
(PrPSc) that is believed to have survived the rendering treatment.
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to completely eliminate all infectivity, thereby creating 
the potential for PrPSc to survive rendering and propa-
gate the disease.
Finally, the mouse model confirmed the efficacy of 
alkaline hydrolysis to inactivate PrPSc because no mice 
succumbed to the disease (Figure 2). The alkaline hy-
drolysis process degraded all proteins, including PrPSc, 
into small peptides and AA, which likely extended past 
the end of the gel during protein separation (Figure 1). 
This argument was further supported by the results 
from staining the PVDF membranes with GelCode 
Blue, which did not identify any residual protein frag-
ments and peptides in the lanes used for separating the 
alkaline hydrolysis treatment group inoculum samples 
(data not shown). The alkaline hydrolysis process dem-
onstrated its potential as a superior alternative to ren-
dering for disposing of biological materials potentially 
infected or contaminated with PrPSc (P < 0.0001). 
Taylor and Woodgate (2003) reported that hot alkali 
processes, like alkaline hydrolysis, are among the few 
disposal methods approved by the European Union and 
World Health Organization for inactivating infectious 
prions.
The scrapie-positive mouse brain homogenate was 
treated for 65 h, which exceeded the 6-h processing 
time required by the European Commission Scientific 
Steering Committee for inactivating prions by almost 
11 times (Thacker, 2004). Ideally, the length of time the 
mouse brain homogenate was hydrolyzed would have 
been closer to 6 h, but because of factors beyond our 
control and because of our interest in validating this 
specific alkaline hydrolysis process in its entirety, this 
was not possible. More specifically, the mouse brain 
homogenate was hydrolyzed in a prototype or beta test-
version of the BioMEER alkaline hydrolysis unit. Since 
that time (December 2006), technological advances and 
advances in cycle optimization should reduce complete 
process times to between 24 to 36 h (K. Morris, owner 
and chief operating officer, Hydrol-Pro Technologies 
Inc., Zephyr Hills, FL, personal communication). In 
addition, it should be noted that the infrastructure at 
the veterinary hospital that was responsible for heat-
ing and cooling the alkaline hydrolysis unit was not 
engineered to accommodate such strenuous demands, 
which may have hindered the efficiency of the process. 
For example, the alkaline hydrolysis unit did not reach 
its peak operating temperature until 9 to 12 h after the 
process was initiated.
The enhanced feed ban of the FDA is set to take 
effect April 27, 2009; as a consequence, the animal ren-
dering and beef packing industries will need to identify 
alternative methods for disposing of these potentially 
infectious materials. We calculated during the study 
that the cost of using alkaline hydrolysis to dispose of 
animal tissues and carcasses was approximately $0.26 
to $0.31/kg ($0.12 to $0.14/lb). However, this cost did 
not include the initial capital investment of purchas-
ing an alkaline hydrolysis unit, as well as the cost of 
building or renovating a facility to accommodate such 
a unit.
Therefore, if the financial costs of this technology are 
acceptable, alkaline hydrolysis should be considered by 
the animal rendering and beef packing industries as an 
alternative to incineration, landfill burial, and render-
ing for disposing of biological material potentially in-
fected or contaminated with prion disease. In addition, 
compared with incineration and landfill burial, alkaline 
hydrolysis yields a sterilized proteinaceous end product 
(effluent) that may have some commercial value such as 
a carbon source for composting and anaerobic digestion, 
Figure 2. Survival curves for mouse treatment groups inoculated with infectious prions (PrPSc)-negative mouse brain material; PrPSc-positive 
mouse brain material; rendered PrPSc-positive mouse brain material; or hydrolyzed PrPSc-positive mouse brain material.
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which could be sold to recuperate expenses incurred 
through its operation. If the effluent were used for one 
of these purposes, it may not be necessary to perform 
the wastewater removal step, which could drastically 
reduce the amount of time required to complete one 
alkaline hydrolysis process.
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